

Table S1. The clinical features of patients carrying pathogenic mutations

Patient ID	Initial Diagnosis	Molecular Diagnosis	Diagnosis after re-diagnosis visit	Mutations segregate disease in family	Comments	Age (month)	Age (last visit)	Gender	Visual Acuity (VA)		Refraction error				Visual Field (VF)		Macula						Systemic Features									
									V1	V2	V1 (OD)	V2 (OS)	V1 (OS)	V2 (OD)	V1 (OS)	V2 (OS)	Nystagmus	Nystagmo	Photosensitivity	Grossly Normal (Y/N)	CME	Atrophy	Periperal Retina	Other Ocular	ENT involvement	Heart	Kidney/Urinary System	CNS	Other	EEG		
G17	LCA	NR2E3	LCA-like	Yes		2	29	F	N/A	N/A	20/100	20/70	H	N/A	N/A	10°	10°	Y	N	Y	N	N	Band of BMC, fine bone spicules, chondral sclerosis	Right exotropia	N	Hypotension	N	N	Obstructive			
G22	LCA	RDH12	N/A	N/A		Birth	26	M	N/A	N/A	20/80	20/200	H	N/A	N/A	10° + peripheral island	Y	N	N	Macularopathy	N											
G47	LCA	CERKL	LCA-like	N/A		Birth	11	F	10/100	10/100	20/300	20/300	N/A	N/A	N/A	N/A	Y	Says best at night	Y	N/A	N/A	N/A	N/A						46.6µV, 100.0msec, 0.4µV, 46.4msec (OD)			
204	Juv RP	BB51	Juv RP-like	Yes		9	53	F	HMA	HMA	LP	LP	N/A	N/A	N/A	N/A	No central vision, small peripheral island	Y	N	Macularopathy	N				N/A	N/A	N/A	N/A	Irregular periods since 15 yo, slightly amenorrhea?			
241	Juv RP RP	PRPH2 (homozygote or hemizygote)	Juv RP RP		PRPH2 mutations are known cause of adRP, maculopathy, peripheral island dystrophy, but not known to cause LCA	0	30	F	20/40	20/40	15	20/50	20/40	H	Severe constriction of 140°; 140°+ temporal scotomas	140° 7° Vtac	140° 7° Vtac	moderate with several scotomas (140°+)	140° 5° Vtac; 70° N/A with large temporal scotomas	Y	Y	N	Clear	Severe atrophy, multilobulated maculopathy (Fig 3)	Severe attenuation of retinal vessels, RPE atrophy	N	N	N	N	N	N	Non detectable blood and urine ERGs
242	Juv RP RP	PRPH2 (heterozygote or hemizygote)	Juv RP RP		Although the father of 741 is asymptomatic, he clearly showed a maculopathy on retinoscopy and OCT (normal FAF) (Fig 3)	N/A	58	M	N/A	N/A	20/25	20/20	N/A	N/A	N/A	N/A	Constricted	Y	N	N	Clear	Peripheral retinal opacities	Miss pattern, multi-pattern, choroidal opacities	N	N	N	N	N	N	Essentially normal ERGs		
1278	Juv RP	RDH12	N/A	Yes		5	N/A	M	20/150	20/60	N/A	N/A	H	7° N/A	10°	N/A	Y	Y	N	Y	N	Diffuse loss of RPE	Right exotropia	N	N	N	N	N	N	Non detectable		
1303	LCA	TULP1	LCA	N/A		3.5	5	M	10/100	10/100	N/A	N/A	N/A	N/A	N/A	N/A	Y	Y	Y	N	N	No pigment clumping	N	Y	N	N	N	N	Non detectable			
1313	Juv RP	PDE6A	Juv RP	N/A	PRPH2 mutations are known cause of adRP, maculopathy, peripheral island dystrophy, but now known to cause LCA or ARRP	6	N/A	F	20/20	20/20	N/A	N/A	M	65°	60°	N/A	N/A	N	Y	N	N	N	Equatorial mottling, with early bone-spicule like deposits; PPERPE like retinal patterns present at foveal ON FA	N	N	N	N	N	Headaches	Non recordable (nods), reduced (cones)		
1318	LCA	PRPH2(homozygous mutation)	LCA	N/A	PRPH2 mutations are known cause of adRP, maculopathy, peripheral island dystrophy, but now known to cause LCA or ARRP	8mo	29	F	20/70	20/70	20/70	20/70	M	Constricted	Constricted	N/A	N/A	Y	Y	N	N	Y	Sal & proper appearance, discontinuous mottling, crystal-like deposits; 350 deg OU	Y (hearing loss)	N	N	N	N	N	Thyroid nodule (thyrotoxic)	Reduced	
1327	Juv RP	BB51	LCA-like	N/A		16	28	M	HMA	10/250	HMA	15/400	M	temporal 5°	5°	temporal 5°	temporal 5°	Y	Y	N	Diffuse atrophy and granular changes	N	Diffuse RPE atrophy, mottling with granular changes	Strabismus	N	N	N	N	N	N	2 peg shaped indentations/piecrust finger	Non detectable
1413	LCA	GUCY2D	N/A	Yes		N/A	9.5	M	NLP	NLP	NLP	NLP	H	N/A	N/A	N/A	Y	N	N	Y	N	Atrophied macula, pale disc, optic atrophy	Enophthalmos	N	N	N	N	N	N	Absolute (severe), global handicapped development, no language, possibly just right eye, brachycephaly, widow's peak, midline posterior hair whorl	Non detectable	
1382	Juv RP	PDE6A	Juv RP	Yes		3	21	F	N/A	N/A	20/40	20/40	M	N/A	N/A	20° (progressive loss noted)	N	Y	N	Mid-Bull's eye	N	Beaten metal appearance, attenuated vessels, fine bone spicules, hyperpigmented spots	Punctate opacities	N	N	N	N	N	N	Non detectable		
1356	LCA	PRPH2(homozygous mutation)	LCA	N/A	PRPH2 mutations are known cause of adRP, maculopathy, peripheral island dystrophy, but now known to cause LCA or ARRP	Birth	66	F	N/A	N/A	20/400	20/400	N/A	N/A	N/A	10°	10°	10°	10°	Y	Y	N	Flaccid atrophy	Mild ON pallor, attenuated vessels, bone spicules	N	N	N	N	N	N	Diabetes Mellitus x 10 years	Non detectable
1311	Juv RP	PRPH2	Juv RP	N/A	PRPH2 mutations are known cause of adRP, maculopathy, peripheral island dystrophy, but now known to cause LCA or ARRP	Birth	35	F	20/20	20/20	20/40	20/40	M	N/A	N/A	Normal	Y	Y	N	DS minimal macular atrophy	Single bone spicule OD, attenuated vessels, normal disc	LASH in 2000 (myopia)	N	N	N	N	N	N	Decreased			
1425	LCA	S40	Oculopatellar disease	N/A																												
1394	LCA	ALMS1	Alstrom syndrome	Yes	ALMS1 mutations are well known cause of Alstrom syndrome. At his first visit at age 13 he had slowly progressive deafness, learning difficulties, acanthosis nigricans, acropachy, maculopathy, myopathy.	8	11	M	N/A	N/A	10/400	8/400	H	N/A	N/A	15°	40°	Y	Y	N	Flaccid atrophy developed	N	Attenuated vessels	N	N	N	N	N	N	Non detectable		
3557	LCA	CRB1	N/A	Yes		3mo	14 mo	M	N/A	N/A	LP	LP	H	N/A	N/A	N/A	Y	N	N	N	Macular cobwebs	N	Attenuated vessels, scattered dots of RPE atrophy	N	N	N	N	N	N	Epileptic activity/aura noted at 3mo	Non detectable	
3561	LCA	OTX2	N/A	N/A		Infants	47	F	20/200	20/200	19/120	LP	H	20°	<20°	<20°	<20°	Y	Y	Y	Atrophic lesions	N	Progressive degenerative change	N	N	N	N	N	N	N/A		
3561	LCA	GUCY2D	N/A	N/A		Birth	3.5 yrs	M	N/A	N/A	LP	LP	H	N/A	N/A	N/A	Y	N	Y	N	Normal	N	N	N	N	N	N	N	Non detectable			
3645	LCA	CEP290	N/A	N/A		N/A	0	M	N/A	N/A	N/A	N/A	LP	H	Not performed	Y	N/A	N/A	Y	N	Granulare	N	N	N	N	N	N	N	N/A			
3563	LCA	CEP290	N/A	N/A		N/A	3mo	F	N/A	N/A	LP	LP	H	No	N/A	N/A	Y	N/A	N/A	Y	N	N	N	N	N	N	N	N	Non detectable			
3656	LCA	CEP290	N/A	N/A		N/A	20	F	N/A	N/A	20/50	20/40	H	Central and peripheral islands	Y	Y	N	Y	N	N	Granular	N	Granular stenosis	N	N	N	N	N	N	Non detectable		
3670	LCA	TULP1	N/A	N/A		N/A	15	F	N/A	N/A	20/200	20/200	M	Central islands	Y	Y	N	Y	N	N	Granular	N	Grey RPE and loss of outer nuclear envelope	N	N	N	N	N	N	Non detectable		
3676	LCA	B4BP1	N/A	N/A		N/A	6	F	N/A	N/A	LP	LP	H	Not performed	Y	N/A	N/A	N	N	N	Granular	N	Grey RPE and loss of outer nuclear envelope	N	N	N	N	N	N	Non detectable		
3737	LCA	PRPH2	N/A	N/A		N/A	14	M	N/A	N/A	LP	LP	H	Unable to perform	Y	Y	N	Y	N	N	Granular	N	Y	N	N	N	N	N	Non detectable			
3679	LCA	SPATA7	N/A	N/A		N/A	17	M	N/A	N/A	20/32	20/32	M	Central islands	Y	Y	N	Y	N	N	Granular	N	Grey RPE	N	N	N	N	N	N	Y (red) No (cones)		
3681	LCA	TULP1	N/A	N/A		N/A	25	F	N/A	N/A	20/80	20/80	No	Central and peripheral islands	Y	Y	Y	N	N	N	Granular, clumps	N	N	N	Silencing	N	N	N	Non detectable			
3688	LCA	RPGR	LCA or EORD	N/A		partly	0	M	N/A	N/A	20/150	20/150	M	Central and peripheral islands	Y	Y	N	Y	N	N	Granular	N	Y	N	N	N	N	N	Non detectable			
3733	LCA	CBF1	N/A	N/A		N/A	10	M	N/A	N/A	LP	LP	H	Central islands	Y	Y	N	Y	N	N	Granular	N	Y	N	N	N	N	N	Non detectable			
3738	LCA	CBF1	N/A	N/A		N/A	16	F	N/A	N/A	LP	LP	H	Central islands	Y	Y	N	Y	N	N	Granular	N	Y	N	N	N	N	N	Non detectable			
3739	LCA	CEP290	N/A	N/A		N/A	12mo	M	N/A	N/A	N/A	N/A	H	N/A	N/A	Y	N/A	N/A	Y	N	N	Granular	N	Y	N	N	N	N	N	Non detectable		
3740	LCA	RDH12	N/A	N/A		N/A	24	M	N/A	N/A	LP	LP	H	Peripheral island	Y	Y	N	Y	N	N	Granular	N	Big and atrophy	N	N	N	N	N	N	Non detectable		
3745	LCA	RDH12	N/A	N/A		N/A	24	M	N/A	N/A	LP	LP	H	Peripheral island	Y	Y	N	Y	N	N	Granular	N	Big and atrophy	N	N	N	N	N	N	Non detectable		
3746	LCA	APL1	N/A	N/A		N/A	11	M	N/A	N/A	LP	LP	H	Central islands	Y	Y	N	Y	N/A	N/A	Granular	N	Y	N	N	N	N	N	N/A			
3748	LCA	CBLN3	LCA-like	N/A		N/A	6	M	N/A	N/A	LP	LP	H	Peripheral island	Y	Y	N	Y	N/A	N/A	Thinned appearance	N	Y	N	N	N	N	N	Non detectable			
3750	LCA	GUCY2D	N/A	N/A		N/A	22	F	N/A	N/A	20/160	20/200	No	Normal V-4e	Y	Y	N	Y	N	N	Thinned appearance	N	Y	N	N	N	N	N	Non detectable			
3752	LCA	ICGB1	N/A	N/A		N/A	8	M	N/A	N/A	LP	LP	H	N/A	N/A	Y	N/A	N/A	Y	N	N	Scattered pigment	N	Tubes inserted for ear infections	N	N	N	N	N	N	Non detectable	
3754	LCA	APL1	N/A	N/A		N/A	22	F	N/A	N/A	LP	LP	H	No detectable field	Y	Y	N	Y	N/A	N/A	Granular clumps	N	N	N	N	N	N	Asthma	Non detectable			
3757	LCA	TULP1	N/A	N/A		N/A	16	F	N/A	N/A	20/400	20/400	H	Central islands	Y	N/A	Y	N	N	N	No pigment	N	N	N	N	N	N	N	Non detectable			
3771	LCA	TULP1	N/A	N/A		N/A	36	M	N/A	N/A	LP	LP	H	Central islands	Y	Y	N	Y	N/A	N/A	Thinned appearance	N	N	N	N	N	N	N	Non detectable			
3773	LCA	IMPNE	LCA-like	N/A		N/A	23	M	N/A	N/A	20/200	20/200	H	Central islands	Y	Y	N	Y	N/A	N/A	No pigment	N	N	N	N	N	N	N	Non detectable			
3776	LCA	ALMS1	N/A	N/A		N/A	21	F	N/A	N/A	20/40	20/50	H	Central and peripheral islands	Y	Y	N	Y	N/A	N/A	Big and atrophy	N	N	N	N	N	N	Gastritis	Non detectable			
3784	LCA	PHEX	N/A	N/A		N/A	19	F	N/A	N/A	20/400	20/400	M	Central island only	Y	Y	N	Y	N	N	No pigment	N	N	N	N	N	N	Hemoglobinopathy?	Non detectable			
3793	LCA	CFP290	N/A	N/A		N/A	23	M	N/A	N/A	LP	LP	H	No detectable field	Y	Y	N	Y	N/A	N/A	Granular	N	N	N	N	N	N	N	Non detectable			
3795	LCA	SMNPF200	N/A	N/A		N/A	7	F	N/A	N/A	20/250	20/250	H	Normal	Y	N	N	Y	N/A	N/A	Granular	N	N	N	N	N	N	Learning disability	Reduced (ODS, LI (ODS))			
3796	LCA	ROCR1	N/A	N/A		N/A	13	M	N/A	N/A	20/250	20/250	H	Central islands	Y	Y	N	Y	N/A	N/A	No pigment	N	N	N	N	N	N	N	Non detectable			
3799	LCA	GUCY2D	N/A	N/A		N/A	19	F	N/A	N/A	20/240	20/400	N/A	Central islands	Y	N	N	Y	N	N	No pigment	N	N	N	N	N	N	N	Non detectable			
3816	LCA	RDH12	N/A	N/A		Birth	6	F	10/80	20/60	20/400	20/400	H	N/A	N/A	N/A	Y	Y	N	Significant maculopathy	N	W										

Table S2. Overview of regions with poor coverage

	GC%	Length	Complexity / length	Tm	Coverage
Avg. (low cvg. regions)	0.596501	248.8409	0.466871	87.11466	0.7
Standard dev. (low)	0.130444	235.3588	0.105623	6.578099	1.2
Avg. (other regions)	0.500257	252.8994	0.424738	82.36241	297.3
Standard dev. (others)	0.10179	548.7422	0.107763	5.65267	132.8
T-test (low vs others)	1.49E-05	0.913384	0.011909	2.1E-05	0

This table displays the GC content, length, complexity/length, and melting temperature of both the low coverage data set, and the set of all other exons, as well as their standard deviations. Complexity was measured as the difference in storage size of a compressed vs uncompressed probe (using the linux algorithm compress), and as such is an inverse measurement of the sequence complexity of the probe. Tm is the melting temperature of the probe. GC% calculates the percentage of base pairs that are either Guanine or Cytosine. A T-test was performed between these two groups, and statistically significant differences were found in the GC content, complexity/ length, and melting temperature of low coverage probes when compared to their normal counterparts.

Table S3. List of all low coverage capture regions

Hg 19 position	Gene	NM#	CDS Exon	GC%	Length	Complexity / length	Duplicated regions	Coverage	
chr1:196658550-196658744	CFH	NM_000186	8	0.410256	195	0.461538	80.54598	Yes	0.0
chr1:196714947-196715129	CFH	NM_000186	21	0.431694	183	0.464481	81.25679	Yes	0.0

chr1:196716241-196716634	CFH	NM_000186	22	0.337563	394	0.555838	78.86064	Yes	0.5
chr2:73826528-73826648	ALMS1	NM_015120	10	0.404959	121	0.413223	78.76065	Yes	0.0
chr2:73830368-73830431	ALMS1	NM_015120	14	0.453125	64	0.328125	77.0552	Yes	0.0
chr4:47972913-47973117	CNGA1	NM_001142564	1	0.507317	205	0.482927	84.65055	Yes	0.0
chr5:178421442-178422124	GRM6	NM_000843	4	0.775988	683	0.633968	97.37303	No	1.3
chr7:33140143-33140173	RP9	NM_203288	2	0.451613	31	0.129032	68.67667	Yes	0.0
chr7:33148833-33149002	RP9	NM_203288	1	0.752941	170	0.5	94.21899	No	0.8
chr8:63998377-63998612	TTPA	NM_000370	1	0.762712	236	0.533898	95.44212	No	3.3
chrX:77359666-77359902	PGK1	NM_000291	1	0.632911	237	0.50211	90.12924	No	0.0
chrX:77365364-77365414	PGK1	NM_000291	2	0.392157	51	0.27451	72.56408	Yes	0.0
chrX:77369513-77369657	PGK1	NM_000291	4	0.531034	145	0.455172	84.61371	Yes	1.2
chrX:77373548-77373667	PGK1	NM_000291	6	0.558333	120	0.391667	85.01457	Yes	0.5
chrX:77380371-77380548	PGK1	NM_000291	9	0.52809	178	0.466292	85.13227	Yes	1.1
chrX:77380824-77380922	PGK1	NM_000291	10	0.565657	99	0.383838	84.43099	Yes	0.7
chrX:77381287-77382324	PGK1	NM_000291	11	0.365125	1038	0.630058	80.77801	Yes	0.0
chrX:153409725-153409869	OPN1LW	NM_020061	1	0.627586	145	0.448276	88.57233	Yes	0.7
chrX:153416128-153416424	OPN1LW	NM_020061	2	0.579125	297	0.525253	88.35018	Yes	0.0
chrX:153421769-153422008	OPN1LW	NM_020061	5	0.541667	240	0.5125	86.41457	Yes	4.9
chrX:153424291-153424507	OPN1LW	NM_020061	6	0.520737	217	0.483871	85.33566	Yes	0.0
chrX:153448085-153448278*	OPN1MW	NM_000513	1	0.634021	194	0.494845	89.7071	Yes	0.5
chrX:153453259-153453555	OPN1MW	NM_000513	2	0.579125	297	0.525253	88.35018	Yes	0.2
chrX:153461421-153462351	OPN1MW	NM_000513	6	0.568206	931	0.61869	89.04897	Yes	0.2
chrX:153485203-153485396*	OPN1MW2	NM_001048181	1	0.634021	194	0.494845	89.7071	Yes	0.7
chrX:153490377-153490673	OPN1MW2	NM_001048181	2	0.579125	297	0.525253	88.35018	Yes	0.4
chrX:153498539-153499469	OPN1MW2	NM_001048181	6	0.568206	931	0.621912	89.04897	Yes	0.0
chr10:85954412-85954571	CDHR1	NM_001171971	1	0.76875	160	0.5	94.68332	No	1.3
chr10:95360928-95360993	RBP4	NM_006744	UTR	0.80303	66	0.363636	91.63806	No	0.0
chr10:124221041-124221640	HTRA1	NM_002775	1	0.795	600	0.64	98.05124	No	0.7
chr11:12695969-12696381	TEAD1	NM_021961	UTR	0.784504	413	0.588378	97.24357	No	1.0
chr11:68080108-68080273	LRP5	NM_002335	1	0.825301	166	0.53012	97.11488	No	0.0

chr14:68168603-68168652	RDH12	NM_152443	UTR	0.58	50	0.26	80.06957	Yes	0.0
chr16:16297267-16297470	ABCC6	NM_001171	7	0.563725	204	0.485294	86.95134	Yes	3.1
chr16:16302585-16302716	ABCC6	NM_001171	6	0.560606	132	0.439394	85.48654	Yes	0.0
chr16:16306042-16306103	ABCC6	NM_001171	5	0.612903	62	0.306452	83.35409	Yes	0.1
chr16:16308181-16308306	ABCC6	NM_001171	4	0.619048	126	0.452381	87.70227	Yes	1.3
chr16:16313411-16313539	ABCC6	NM_001171	3	0.55814	129	0.395349	85.29733	Yes	0.0
chr16:16313679-16313804	ABCC6	NM_001171	2	0.547619	126	0.396825	84.7737	Yes	0.0
chr16:16315506-16315688	ABCC6	NM_001171	1	0.606557	183	0.486339	88.42619	Yes	0.3
chr16:16317256-16317328	ABCC6	NM_001171	UTR	0.739726	73	0.356164	89.76903	Yes	0.0
chr16:53656131-53656268	RPGRIPI1L	NM_015272.2	23	0.608696	138	0.427536	87.62291	Yes	0.5
chr17:6459705-6459877	PITPNM3	NM_001165966	1	0.849711	173	0.543353	98.23755	No	0.0
chr17:79503901-79504155	FSCN2	NM_012418	5	0.729412	255	0.513725	94.23467	No	4.5

Table S3 lists all regions of poor coverage, along with their GC content, length, complexity per unit length, predicted melting temperature and coverage. Duplicated regions are defined as having one or more similar genomic loci that have more than 90% identity in sequence and in homologous length, supported by UCSC genome browser BLAT results (<http://genome.ucsc.edu/cgi-bin/hgBlat?command=start>). *: The two regions have the same sequence.

Table S4. *In silico* prediction of novel missense mutations

Gene	Patient ID	Mutations	PhyloP		SIFT		Polyphen2		LRT	MutationTaster
			Score	PhyloP	Score	SIFT	Score	Polyphen2		
ALMS1	3779	c.9764C>G, p.S3255C	0.98	C	1.00	D	0.48	P	N	N
BBS7	1327	c.728G>A, p.C243Y	1.00	C	1.00	D	1.00	D	D	D
CRB1	3319	c.1439G>C, p.C480S	1.00	C	1.00	D	1.00	D	na	D
GUCY2D	1272	c.1933T>C, p.S645P	1.00	C	1.00	D	1.00	D	D	D
GUCY2D	1272	c.2207T>G, p.M736R	1.00	C	0.99	D	1.00	D	N	D
GUCY2D	3611	c.2132C>T, p.P711L	1.00	C	1.00	D	1.00	D	D	D
GUCY2D	3725	c.2678C>T, p.S893F	1.00	C	1.00	D	1.00	D	D	D
GUCY2D	3799	c.743C>G, p.S248W	1.00	C	1.00	D	1.00	D	D	D
INPP5E	3773	c.1861C>T, p.R621W	1.00	C	1.00	D	1.00	D	D	D

<i>PDE6A</i>	1313	c.2333A>T, p.D778V	1.00	C	1.00	D	1.00	D	D	D
<i>RDH12</i>	3740	c.692G>A, p.G231D	0.99	C	1.00	D	1.00	D	D	D
<i>SNRNP200</i>	3795	c.3133C>A, p.P1045T	1.00	C	1.00	D	1.00	D	D	D
<i>TULP1</i>	1268	c.1277C>T, p.P426L	1.00	C	1.00	D	1.00	D	D	D
<i>TULP1</i>	1268	c.1518C>A, p.F506L	0.75	N	1.00	D	1.00	D	D	D
<i>TULP1</i>	3681	c.1064A>T, p.D355V	1.00	C	0.99	D	0.99	D	D	D
<i>TULP1</i>	3771	c.961T>G, p.Y321D	1.00	C	1.00	D	1.00	D	D	D

#The prediction score and results are generated from PhyloP, SIFT, Polyphen2, LRT, and MutationTaster, and compiled by dbNSFP.

C: conserved; D: damaging; N: neutral; P, possibly damaging; na: not available. When dbNSFP don't have pre-computed scores for specific mutation, we searched the online server provided by each program to get the original prediction score, then convert the score to dbNSFP score according to dbNSFP standard.

Table S5. Prescreening information for subset of our patient cohort

Patient ID	LCA APEX		arRP APEX							Solved by NGS: known	Why prescreening failed	
	array	DATE	array	DATE	RPGRIP1	AIPL1	RPE65	CRX	CRB1	GUCY2D		
54	yes	Oct-03			yes	yes	yes	yes	yes	yes	yes	A
208	yes	Oct-03			yes	yes	yes	yes	yes	yes		
251					yes				yes	yes		
285	yes	Oct-03			yes	yes	yes	yes	yes			
291	yes	Oct-03			yes	yes	yes	yes	yes			
361					yes	yes	yes	yes				
393					yes	yes	yes	yes		yes		B
398					yes	yes	yes	yes		yes		B
408	yes	Oct-03	Apr-08		yes	yes		yes	yes	yes		
418	yes	Oct-03			yes	yes		yes	yes		yes	A, B
432	yes	Oct-03			yes	yes	yes	yes	yes			
486	yes	Oct-03			yes	yes	yes	yes	yes			
489												
512	yes	Oct-03	Aug-07		yes	yes	yes	yes	yes	yes		

518	yes	Oct-03						
617	yes	Oct-03	yes	yes	yes	yes	yes	
622	yes	Oct-03	yes	yes	yes	yes	yes	yes
635			yes	yes	yes	yes	yes	A
647			yes	yes	yes	yes	yes	
690	yes	Oct-03	yes	Jun-05	yes	yes	yes	yes
704	yes	Oct-03			yes	yes	yes	
787			yes		yes	yes	yes	
789					yes	yes	yes	
1171					yes	yes	yes	
1174					yes	yes	yes	
1248		yes	Apr-05	yes	yes	yes	yes	
1250					yes	yes	yes	
1251					yes	yes	yes	yes
1253					yes	yes	yes	
1255					yes	yes	yes	
1257					yes	yes	yes	
1259					yes	yes	yes	yes
1262					yes	yes	yes	
1268					yes	yes	yes	yes
1269					yes	yes	yes	
1271					yes	yes	yes	yes
1272					yes	yes	yes	yes
1273					yes	yes	yes	
1275					yes	yes	yes	
1278					yes	yes	yes	yes
1290					yes	yes	yes	
1303					yes	yes	yes	yes
1311					yes	yes	yes	
1312					yes	yes	yes	
1313					yes	yes	yes	

1314		yes	yes	yes	yes	yes		
1315		yes	yes	yes	yes	yes	yes	C
1318		yes	yes	yes	yes	yes		
1327		yes	yes	yes	yes	yes		
1331		yes	yes	yes	yes	yes		
1332		yes	yes	yes	yes	yes		
1379			yes	yes	yes	yes		
1380			yes	yes	yes	yes		
1381			yes	yes	yes	yes		
1413				yes	yes	yes	yes	C
1472				yes	yes	yes		
1473				yes	yes	yes	yes	C
1842								
1896								
3062								
3075								
3256								
3294	yes	Apr-08						
3311	yes	Apr-08						
3319	yes	Apr-08				yes	A	
3425								
3443	yes	Apr-09						
3494								
3550	yes	Jun-10						
3551								
3557						yes	C	
3561	yes	Apr-09				yes	A	
3577						yes	C	
3582								
3596	yes	Apr-09						
3611						yes	C	

3628						
3698	yes	Jun-10				
3719						
3722			yes	C		
3725			yes	C		
3916			yes	C		
3973						
3985	yes	Jun-10				
4012						
4013						
4016						
4019			yes	C		

Columns in table S5: LCA APEX array: this indicates whether or not the sample had been screened by LCA APEX array; arRP APEX array: this indicates whether or not the sample had been screened by autosomal recessive RP APEX array; Date: the date when the sample was screened by the array; Six columns with gene names: this indicates whether or not the sample had been Sanger sequenced for the frequently mutated exons in the corresponding gene; Solved by NGS: known LCA gene: this indicates whether or not mutations in known LCA genes were identified by our targeted NGS method in the sample; Why prescreening failed: this is to explain why the mutations in known LCA genes had not been captured by the prescreening (A: the mutations had not been covered by the array; B: the mutant exon had not been covered by Sanger sequencing, only the frequently mutated exons in the corresponding gene were Sanger sequenced; C: the sample had neither been screened by LCA APEX array nor been Sanger sequenced for the corresponding genes identified in the sample).